Northern Trust Corp lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,430,476 shares of the biopharmaceutical company’s stock after purchasing an additional 116,780 shares during the quarter. Northern Trust Corp owned 1.26% of Gilead Sciences worth $1,162,949,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Gilead Sciences by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after purchasing an additional 310,607 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Gilead Sciences by 1.0% in the second quarter. Franklin Resources Inc. now owns 14,516,058 shares of the biopharmaceutical company’s stock worth $1,027,436,000 after purchasing an additional 136,884 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Gilead Sciences by 9.3% in the second quarter. Legal & General Group Plc now owns 7,004,455 shares of the biopharmaceutical company’s stock worth $495,778,000 after purchasing an additional 596,992 shares during the last quarter. Finally, TIAA CREF Investment Management LLC raised its stake in shares of Gilead Sciences by 8.8% in the second quarter. TIAA CREF Investment Management LLC now owns 6,267,271 shares of the biopharmaceutical company’s stock worth $443,597,000 after purchasing an additional 509,260 shares during the last quarter. Hedge funds and other institutional investors own 76.30% of the company’s stock.
In other Gilead Sciences news, EVP Gregg H. Alton sold 50,000 shares of the business’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the completion of the sale, the executive vice president now owns 113,237 shares of the company’s stock, valued at $8,945,723. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the sale, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The disclosure for this sale can be found here. Insiders have sold 666,819 shares of company stock valued at $52,303,086 in the last three months. 1.30% of the stock is currently owned by corporate insiders.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $72.46 on Monday. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The stock has a market capitalization of $94,652.25, a PE ratio of 7.56, a price-to-earnings-growth ratio of -1.21 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the previous year, the company posted $2.75 earnings per share. Gilead Sciences’s revenue for the quarter was down 13.2% on a year-over-year basis. equities research analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.87%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.69%.
Several research firms have recently weighed in on GILD. Leerink Swann boosted their price target on Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a research note on Thursday, October 19th. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Berenberg Bank restated a “buy” rating and issued a $86.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research note on Sunday, August 20th. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, October 19th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $84.87.
COPYRIGHT VIOLATION WARNING: “Northern Trust Corp Buys 116,780 Shares of Gilead Sciences, Inc. (GILD)” was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://transcriptdaily.com/2017/11/27/northern-trust-corp-buys-116780-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.